Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Mitacs brings innovation to more people in more places across Canada and around the world.
Learn MoreWe work closely with businesses, researchers, and governments to create new pathways to innovation.
Learn MoreNo matter the size of your budget or scope of your research, Mitacs can help you turn ideas into impact.
Learn MoreThe Mitacs Entrepreneur Awards and the Mitacs Awards celebrate inspiring entrepreneurs and innovators who are galvanizing cutting-edge research across Canada.
Learn MoreDiscover the people, the ideas, the projects, and the partnerships that are making news, and creating meaningful impact across the Canadian innovation ecosystem.
Learn MoreThe project addresses urgent and clinically-relevant questions related to COVID-19, which causes in some patients life-threatening respiratory distress, septic shock and organ failures. Patients in intensive care units were found to have significantly higher levels of high mobility group box 1 (HMGB1) than patients with milder symptoms. HMGB1 is a protein normally found in the cell nucleus that is released outside the cell under inflammatory conditions such as viral infections. Although its role in COVID-19 pathology remains unclear, its levels in the blood are correlated to the severity of sepsis and organ dysfunction, and could contribute to the higher mortality rate observed in patients with other inflammatory conditions.
The reason for targeting HMGB1 in COVID-19 rests upon its key role as an inflammatory protein increased in COVID-19. Our main goal is to modulate its level and activity in COVID-19-associated inflammatory response using pharmacological and nanotherapeutical agents – JN2019, JN2020, fisetin and dPGS – which target different steps in HMGB1 regulation. COVID-19-associated inflammation will be modelled in human cells of organs most impacted by the virus (lungs, kidneys, brain) using the main viral protein (S-protein). Cell death resulting from excessive inflammation will be correlated to HMGB1 protein modifications and activity.
Dusica Maysinger
Issan Zhang
JN Nova
Pharmacy / Pharmacology
Professional, scientific and technical services
McGill University
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.